CD19 and CD3 — Drug Target

All drugs that target CD19 and CD3 — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Bispecific monoclonal antibody

Phase 2 pipeline (1)

• Blinatumomab plus Reduced-dose Chemotherapy · Xianmin Song, MD · Bispecific monoclonal antibody · Oncology
  Blinatumomab targets CD19 and CD3 on T cells, leading to T cell activation and killing of B cell malignancies.